Questcor Pharmaceuticals Inc. has signed a definitive agreement to acquire all
issued and outstanding shares of BioVectra Inc., for an upfront payment of nearly $50 million
The transaction agreements for Synacthen and Synacthen Depot include $60 million up front, at least $75 million in
additional payments, as well as royalties on net sales
From Jan. 1, 2011, to Dec. 31, 2013, Questcor said, 1,022 patients reported 3,100 adverse events while on Acthar. The filing said that many users
of the drug were seriously ill and faced life-threatening health risks. Acthar generates some 95 percent of Questcor’s revenues.
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.